DZ3382A1 - Sel de thiazolidinedione pour le traitement du diabete sucre - Google Patents

Sel de thiazolidinedione pour le traitement du diabete sucre

Info

Publication number
DZ3382A1
DZ3382A1 DZ013382A DZ013382A DZ3382A1 DZ 3382 A1 DZ3382 A1 DZ 3382A1 DZ 013382 A DZ013382 A DZ 013382A DZ 013382 A DZ013382 A DZ 013382A DZ 3382 A1 DZ3382 A1 DZ 3382A1
Authority
DZ
Algeria
Prior art keywords
treatment
sugar diabetes
thiazolidinedione
salt
thiazolidinedione salt
Prior art date
Application number
DZ013382A
Other languages
English (en)
French (fr)
Inventor
Andrew Simon Craig
Tim Chien Ting Ho
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ3382A1 publication Critical patent/DZ3382A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
DZ013382A 2000-06-08 2001-06-08 Sel de thiazolidinedione pour le traitement du diabete sucre DZ3382A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0014006.1A GB0014006D0 (en) 2000-06-08 2000-06-08 Novel pharmaceutical
PCT/GB2001/002567 WO2001094344A1 (en) 2000-06-08 2001-06-08 Thiazolidinedione salt for treatment of diabetes mellitus

Publications (1)

Publication Number Publication Date
DZ3382A1 true DZ3382A1 (fr) 2001-12-13

Family

ID=9893257

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013382A DZ3382A1 (fr) 2000-06-08 2001-06-08 Sel de thiazolidinedione pour le traitement du diabete sucre

Country Status (23)

Country Link
EP (1) EP1296980A1 (cs)
JP (1) JP2003535862A (cs)
KR (1) KR20030007918A (cs)
CN (1) CN1443186A (cs)
AP (1) AP2002002673A0 (cs)
AU (1) AU2001264078A1 (cs)
BG (1) BG107357A (cs)
BR (1) BR0111536A (cs)
CA (1) CA2411065A1 (cs)
CZ (1) CZ20023966A3 (cs)
DZ (1) DZ3382A1 (cs)
EA (1) EA200300005A1 (cs)
GB (1) GB0014006D0 (cs)
HU (1) HUP0301137A3 (cs)
IL (1) IL153279A0 (cs)
MA (1) MA25753A1 (cs)
MX (1) MXPA02012100A (cs)
NO (1) NO20025883L (cs)
OA (1) OA12284A (cs)
PL (1) PL360592A1 (cs)
SK (1) SK17142002A3 (cs)
WO (1) WO2001094344A1 (cs)
ZA (1) ZA200209954B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39384E1 (en) 1993-09-01 2006-11-07 Smithkline Beecham P.L.C. Substituted thiazolidinedione derivatives
DE102005034406A1 (de) * 2005-07-22 2007-02-01 Ratiopharm Gmbh Neue Salze von Rosiglitazon
EP2016076A2 (en) * 2007-01-22 2009-01-21 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
WO2010021745A2 (en) * 2008-08-21 2010-02-25 Teva Pharmaceutical Industries Ltd. Polymorphic forms of rosiglitazone hydrobromide and processes for their preparation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
BG107357A (bg) 2003-08-29
PL360592A1 (en) 2004-09-20
CA2411065A1 (en) 2001-12-13
CN1443186A (zh) 2003-09-17
AU2001264078A1 (en) 2001-12-17
CZ20023966A3 (cs) 2003-04-16
BR0111536A (pt) 2003-07-01
JP2003535862A (ja) 2003-12-02
GB0014006D0 (en) 2000-08-02
NO20025883D0 (no) 2002-12-06
EA200300005A1 (ru) 2003-04-24
MXPA02012100A (es) 2003-04-25
AP2002002673A0 (en) 2002-12-31
KR20030007918A (ko) 2003-01-23
MA25753A1 (fr) 2003-04-01
ZA200209954B (en) 2003-10-10
IL153279A0 (en) 2003-07-06
EP1296980A1 (en) 2003-04-02
WO2001094344A1 (en) 2001-12-13
HUP0301137A2 (hu) 2003-08-28
NO20025883L (no) 2003-02-03
HUP0301137A3 (en) 2005-04-28
OA12284A (en) 2003-11-10
SK17142002A3 (sk) 2003-10-07

Similar Documents

Publication Publication Date Title
EP1831385A4 (en) ENZYME FOR STRENGTH PROCESSING
MA25820A1 (fr) Combinaisons d'inhibiteurs de peptidase iv de dipeptidyle et d'autres agents antidiabetiques pour le traitement du mellitus de diabete.
EP1638950A4 (en) CYCLOHEXYLGLYCIN DERIVATIVES AS DIPEPTIDYLPEPTIDASEINHIBITORS FOR THE TREATMENT OF BZW. PREVENTION OF DIABETES
MA25823A1 (fr) Compositions pour le traitement de l'eau.
EP1357908A4 (en) "ACYLSULFAMIDES FOR THE TREATMENT OF FATIBILITY, DIABETES AND LIPID DISORDERS"
DZ2936A1 (fr) Composition nouvelle à libération modifiée pour letraitement du diabète.
DK1093370T3 (da) Farmaceutisk præparat til behandling af diabetes
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
ATE320257T1 (de) (s,s)-reboxetine zur behandlung chronischer schmerzen
MA26951A1 (fr) Derives de pyrazole pour le traitement de maladies virales
MA25847A1 (fr) Composition pour le traitement du dysfonctionnement endothelial.
EP1758854A4 (en) PYRROLIDIN-3-YL COMPOUNDS SUITABLE AS BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE
EP1581243A4 (en) ORAL LACTOFERRIN FOR SEPSIS TREATMENT
DZ3382A1 (fr) Sel de thiazolidinedione pour le traitement du diabete sucre
FR2786390B1 (fr) Cotyle de correction pour emploi dans le traitement de pathologies de la hanche
MA28583B1 (fr) Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale
EP1359885A4 (en) NOS-HEMMER FOR THE TREATMENT OF WRINKLES
EP1750513A4 (en) USE OF GPCR54 LIGANDS FOR THE TREATMENT OF BARRENESS
FR2835851B1 (fr) Composition pour le traitement d'alliages de magnesium
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
EP1172113A4 (en) MEDICINE FOR AUTONOMOUS NEUROPATHIES
EP1687275A4 (en) PYRIDINE-4-YLAMINE COMPOUNDS SUITABLE FOR THE TREATMENT OF NEUROPATHIC PAIN
EP1298216A4 (en) PROCESS FOR TREATMENT USING AN ENZYME
FR2849599B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete